Clinical investigation of docetaxel combined with nedaplatin in the treatment of recurrent epithelial ovarian cancer in elderly women
10.3760/cma.j.issn.0254-9026.2013.08.011
- VernacularTitle:多西他赛联合奈达铂治疗老年妇女复发性上皮性卵巢癌的临床研究
- Author:
Ying CUI
;
Dan ZHOU
;
Linlin MA
;
Guihua SHEN
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasms;
Antineoplastic combined chemotherapy protocols
- From:
Chinese Journal of Geriatrics
2013;32(8):836-839
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of concomitant docetaxal (DTX) and nedaplatin (NDP) therapy for recurrent epithelial ovarian cancer in elderly women.Methods Totally 42 elderly patients with histologically confirmed recurrent epithelial ovarian cancer received chemotherapy with DTX combined with NDP.DTX with the dose of 60-70 mg/m2 was administered intravenously on day 1,followed by NDP with the dose of 70-80 mg/m2 given intravenously on day 2.The treatment was repeated every 3 weeks.The efficacy was evaluated according to response evaluation criteria in solid tumors (RECIST) and serum CA125 level.Adverse reactions were assessed according to performance and standard criteria in toxicity of anticancer agents of WTO.Results 4 patients were switched to other chemotherapy strategies due to progression of disease after 2 courses of treament,and the other patients completed 4 to 6 courses.Among 42 patients,18 cases (42.9％)showed complete remission,10 cases (23.8％) showed partial remission,6 cases (14.3％) were in stable conditions,and 8 cases (19.0％) progressed to severe disease.The median progression-free survival (PFS) time was 7 months,and the efficacy rate (complete and partial remission) was 66.7％(28/42).The main adverse effects were alopecia,nausea and vomit,and leucopenia.Patients could get remission by receiving drug therapy.Conclusions Docetaxel plus nedaplatin therapy has a good therapeutic effect with low incidence of adverse reactions,high safety and well tolerance in elderly platinum-sensitive women and in those with platinum-resistant recurrent epithelial ovarian cancer.
